Metrion Biosciences Secures £3.7M Funding for Drug Discovery
Metrion Biosciences, a Cambridge-based ion channel CRO and drug discovery company, recently secured £3.7M in funding. Maven Capital Partners and Gresham House Ventures led the investment round. The company plans to utilize the funds to expand its laboratories in Cambridge, UK, acquire specialized equipment, and enhance its global marketing activities. Metrion Biosciences is a contract research organization that specializes in providing ion channel drug discovery services to its clients. Their approach offers a flexible and dedicated service tailored to meet each customer's specific requirements. The experienced ion channel team at Metrion provides rapid reporting and data interpretation to support their offerings, which include compound screening assays, detailed characterization of lead compounds in human cells and native tissue, and confirmation of efficacy in stem cell and other phenotypic models.
Metrion Biosciences also announced the appointment of Dr.
David Milroy and Steve Carle to its board. Concurrently, Dr. Marc Rogers, Dr. Barry Kenny, and Mark Keogh have retired as non-executive directors of the company. These changes in the board composition reflect the company's continuous efforts to strengthen its leadership and expertise in the field. With the new funding and the additions to its board, Metrion Biosciences is well-positioned to further advance its research and drug discovery capabilities.
The funding raised by Metrion Biosciences underscores the growing importance and demand for ion channel drug discovery services. These services play a vital role in identifying potential drug candidates that target ion channels, which are involved in numerous physiological processes. With its expanded laboratories and enhanced marketing activities, Metrion Biosciences is poised to address the evolving needs of its clients and contribute to the development of innovative treatments for a range of diseases and conditions.
They've invested in Metrion Biosciences
Get to know these Biotech investors
Click here for a full list of 7,526+ startup investors in the UK